Pfizer’s (NYSE:PFE) Pfizer Oncology will present updated data in chronic myeloid leukemia for its oral Abl and SRC kinase inhibitor, Bosulif (bosutinib), which was recently okayed by the FDA . In addition, new data in acute lymphoblastic leukemia and non-Hodgkin’s lymphoma for inotuzumab ozogamicin, a CD-22 directed antibody drug conjugate which is currently being evaluated in two Phase 3 trials, will be presented at the 54th Annual Meeting of the American Society of Hematology on December 8th.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>